Kairos Pharma's NYSE American debut saw a 30% drop in shares to $2.81. The cancer-focused biopharmaceutical company priced its IPO at $4 per share, matching its estimate.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Kairos Pharma's NYSE American debut saw a 30% drop in shares to $2.81. The cancer-focused biopharmaceutical company priced its IPO at $4 per share, matching its estimate.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.